Goldman Sachs initiates Aclaris at Buy citing potential in lead asset

Dec. 01, 2022 2:23 PM ETAclaris Therapeutics, Inc. (ACRS)By: Dulan Lokuwithana, SA News Editor

Wall Street New York City

aluxum/E+ via Getty Images

  • Aclaris Therapeutics (NASDAQ:ACRS), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25 per share target, citing prospects for its lead candidate zunsemetinib.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.